Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 4/2009

Open Access 01-04-2009 | Review Article

Nuclear imaging in cardiac amyloidosis

Authors: A. W. J. M. Glaudemans, R. H. J. A. Slart, C. J. Zeebregts, N. C. Veltman, R. A. Tio, B. P. C. Hazenberg, R. A. J. O. Dierckx

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 4/2009

Login to get access

Abstract

Amyloidosis is a disease characterized by depositions of amyloid in organs and tissues. It can be localized (in just one organ) or systemic. Cardiac amyloidosis is a debilitating disease and can lead to arrhythmias, deterioration of heart function and even sudden death. We reviewed PubMed/Medline, without time constraints, on the different nuclear imaging modalities that are used to visualize myocardial amyloid involvement. Several SPECT tracers have been used for this purpose. The results with these tracers in the evaluation of myocardial amyloidosis and their mechanisms of action are described. Most clinical evidence was found for the use of 123I-MIBG. Myocardial defects in MIBG activity seem to correlate well with impaired cardiac sympathetic nerve endings due to amyloid deposits. 123I-MIBG is an attractive option for objective evaluation of cardiac sympathetic level and may play an important role in the indirect measurement of the effect of amyloid myocardial infiltration. Other, less sensitive, options are 99mTc-aprotinin for imaging amyloid deposits and perhaps 99mTc-labelled phosphate derivatives, especially in the differential diagnosis of the aetiology of cardiac amyloidosis. PET tracers, despite the advantage of absolute quantification and higher resolution, are not yet well evaluated for the study of cardiac amyloidosis. Because of these advantages, there is still the need for further research in this field.
Literature
1.
Selvanayagam JB, Hawkins PN, Paul B, et al. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 2007;50(22):2101–10.PubMedCrossRef
2.
Hazenberg BP, van Gameren II, Bijzet J, et al. Diagnostic and therapeutic approach of systemic amyloidosis. Neth J Med 2004;62(4):121–8.PubMed
3.
Westermark P, Benson MD, Buxbaum JN, et al. Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 2005;12(1):1–4.PubMedCrossRef
4.
Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 1998;91:141–57.PubMedCrossRef
5.
Dubrey SW, Cha K, Simms RW, et al. Electrocardiography and Doppler echocardiography in secondary (AA) amyloidosis. Am J Cardiol 1996;77:313–5.PubMedCrossRef
6.
7.
Ng B, Connors LH, Davidoff R, et al. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med 2005;165:1425–9.PubMedCrossRef
8.
Camacho V, Carrio I. Targeting neuronal dysfunction and receptor imaging. Curr Opin Biotechnol 2007;18(1):60–4.PubMedCrossRef
9.
Hongo M, Urushibata K, Kai R, et al. Iodine-123 metaiodobenzylguanidine scintigraphic analysis of myocardial sympathetic innervation in patients with AL (primary) amyloidosis. Am Heart J 2002;144(1):122–9.PubMedCrossRef
10.
Yamashina S, Yamazaki J. Neuronal imaging using SPECT. Eur J Nucl Med Mol Imaging 2007;34(Suppl 1):S62–73.PubMedCrossRef
11.
Nakata T, Shimamoto K, Yonekura S, et al. Cardiac sympathetic denervation in transthyretin-related familial amyloidotic polyneuropathy: detection with iodine-12-MIBG. J Nucl Med 1995;36(6):1040–2.PubMed
12.
Arbab AS, Koizumi K, Toyama K, et al. Scan findings of various myocardial SPECT agents in a case of amyloid polyneuropathy with suspected myocardial involvement. Ann Nucl Med 1997;11(2):139–41.PubMed
13.
Tanaka M, Hongo M, Kinoshita O, et al. Iodine-123 metaiodobenzylguanidine scintigraphic assessment of myocardial sympathetic innervation in patients with familial amyloid polyneuropathy. J Am Coll Cardiol 1997;29(1):168–74.PubMedCrossRef
14.
Delahaye N, Dinanian S, Slama MS, et al. Cardiac sympathetic denervation in familial amyloid polyneuropathy assessed by iodine-123 metaiodobenzylguanidine scintigraphy and heart rate variability. Eur J Nucl Med 1999;26(4):416–24.PubMedCrossRef
15.
Lekakis J, Dimopoulos MA, Prassopoulos V, et al. Myocardial adrenergic denervation in patients with primary (AL) amyloidosis. Amyloid 2003;10(2):117–20.PubMed
16.
Delahaye N, Rouzet F, Sarda L, et al. Impact of liver transplantation on cardiac autonomic denervation in familial amyloid polyneuropathy. Medicine (Baltimore) 2006;85(4):229–38.CrossRef
17.
Delahaye N, Le Guludec D, Dinanian S, et al. Myocardial muscarinic receptor upregulation and normal response to isoproterenol in denervated hearts by familial amyloid polyneuropathy. Circulation 2001;104:2911–6.PubMedCrossRef
18.
Yazaki Y, Isobe M, Takahashi W, et al. Assessment of myocardial fatty acid metabolic abnormalities in patients with idiopathic dilated cardiomyopathy using 123 I BMIPP SPECT: correlation with clinicopathological findings and clinical course. Heart 1999;81(2):153–9.PubMed
19.
De Geeter F, Franken PR, Knapp FF, et al. Relationship between blood flow and fatty acid metabolism in subacute myocardial infarction: a study by means of 99mTc-Sestamibi and I-beta-methyl-iodo-phenyl pentadecanoic acid. Eur J Nucl Med 1994;21:283–91.PubMedCrossRef
20.
Franken PR, De Geeter F, Dendale P, et al. Abnormal free fatty acid uptake in subacute myocardial infarction after coronary thrombolysis: correlation with wall motion and inotropic reserve. J Nucl Med 1994;35:1758–65.PubMed
21.
Nakata T, Tanaka S, Hamagami S, et al. Detection of impaired fatty acid metabolism and dyskinesis in hypertrophic cardiomyopathy with iodine-123-BMIPP. J Nucl Med 1996;37:1679–81.PubMed
22.
Hambye AS, Dobbeleir AA, Vervaet AM, et al. BMIPP imaging to improve the value of sestamibi scintigraphy for predicting functional outcome in severe chronic ischemic left ventricular dysfunction. J Nucl Med 1999;40(9):1468–76.PubMed
23.
Athanasoulis T, Koutsikos J, Moulopoulos LA, et al. Reverse of the differential uptake intensity of Tc-99m MIBI and Tc-99m V-DMSA by multiple myeloma lesions in response to therapy. Clin Nucl Med 2003;28(8):631–5.PubMedCrossRef
24.
Papantoniou VJ, Souvatzoglou MA, Valotassiou VJ, et al. Relationship of cell proliferation (Ki-67) to 99mTc-(V) DMSA uptake in breast cancer. Br Cancer Res 2003;6(2):56–62.CrossRef
25.
Kobayashi H, Sakahara H, Itoh T, et al. Technetium-99m(V)dimercaptosuccinic acid uptake in intra-abdominal massive deposit of amyloid protein. J Nucl Med 1993;34(5):815–7.PubMed
26.
Ohta H, Endo K, Kanoh T, et al. Technetium-99m (V) DMSA uptake in amyloidosis. J Nucl Med 1989;30(12):2049–52.PubMed
27.
Yen TC, Tzen KY, Chen KS, et al. The value of gallium-67 and thallium-201 whole-body and single-photon emission tomography images in dialysis-related β2-microglobulin amyloid. Eur J Nucl Med 2000;27(1):56–61.PubMedCrossRef
28.
Low YH, Ang ES, Goh AS, et al. Technetium-99m (Tc-99m) diphosphono-propanedicarboxylic acid bone tracer uptake and Tc-99m sestamibi distribution in cardiac amyloidosis – a case report. Ann Acad Med Singapore 1995;24(6):898–901.PubMed
29.
Wechalekar K, Ng FS, Poole-Wilson PA, et al. Cardiac amyloidosis diagnosed incidentally by bone scintigraphy. J Nucl Cardiol 2007;14(5):750–3.PubMedCrossRef
30.
Kobayashi T, Sekiya M, Fujiwara Y, et al. A patient with cardiac amyloidosis presenting a rapid increase in technetium-99m-hydroxymethylene diphosphonate accumulation. Ann Nucl Med 1993;7(4):273–6.PubMedCrossRef
31.
Kodama K, Hamada M, Kuwahara T, et al. Rest-redistribution thallium-201 myocardial scintigraphic study in cardiac amyloidosis. Int J Card Imaging 1999;15(5):371–8.PubMedCrossRef
32.
Sojan SM, Smyth DR, Tsopelas C, et al. Pharmacokinetics and normal scintigraphic appearance of 99mTc aprotinin. Nucl Med Commun 2005;26(6):535−9.PubMedCrossRef
33.
Aprile C, Marinone G, Saponaro R, et al. Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labelled aprotinin. Eur J Nucl Med 1995;22(12):1393–401.PubMedCrossRef
34.
Schaadt BK, Hendel HW, Gimsing P, et al. 99mTc-aprotinin scintigraphy in amyloidosis. J Nucl Med 2003;44(2):177–83.PubMed
35.
Han S, Chong V, Murray T, et al. Preliminary experience of 99mTc-aprotinin scintigraphy in amyloidosis. Eur J Haematol 2007;79(6):494–500.PubMedCrossRef
36.
37.
Puille M, Altland K, Linke RP, et al. 99mTc-DPD scintigraphy in transthyretin-related familial amyloidotic polyneuropathy. Eur J Nucl Med Mol Imaging 2002;29(3):376–9.PubMedCrossRef
38.
Karp K, Naslund U, Backman C, et al. Technetium-99m pyrophosphate single-photon emission computed tomography of the heart in familial amyloid polyneuropathy. Int J Cardiol 1987;14(3):365–9.PubMedCrossRef
39.
Leinonen H, Totterman KJ, Korppi-Tommola T, et al. Negative myocardial technetium-99m pyrophosphate scintigraphy in amyloid heart disease associated with type AA systemic amyloidosis. Am J Cardiol 1984;53(2):380–1.PubMedCrossRef
40.
Kulhanek J, Movahed A. Uptake of technetium 99m HDP in cardiac amyloidosis. Int J Cardiovasc Imaging 2003;19(3):225–7.PubMedCrossRef
41.
Casset-Senon D, Secchi V, Arbeille P, et al. Localization of myocardial amyloid deposits in cardiac amyloidosis by Tc-99m pyrophosphate myocardial SPECT: implication for medical treatment. Clin Nucl Med 2005;30(7):496–7.PubMedCrossRef
42.
Falk RH, Lee VW, Rubinow A, et al. Cardiac technetium-99m pyrophosphate scintigraphy in familial amyloidosis. Am J Cardiol 1984;54(8):1150–1.PubMedCrossRef
43.
Ruder MA, Alpert MA, Sanfelippo JF, et al. Symptomatic cardiac amyloidosis in an American family. South Med J 1984;77(7):831–3.PubMed
44.
Sobol SM, Brown JM, Bunker SR, et al. Noninvasive diagnosis of cardiac amyloidosis by technetium-99m-pyrophosphate myocardial scintigraphy. Am Heart J 1982;103(4 Pt 1):563–6.PubMedCrossRef
45.
Schiff S, Bateman T, Moffatt R, et al. Diagnostic considerations in cardiomyopathy: unique scintigraphic pattern of diffuse biventricular technetium-99m-pyrophosphate uptake in amyloid heart disease. Am Heart J 1982;103(4 Pt 1):562–3.PubMedCrossRef
46.
Ali A, Turner DA, Rosenbush SW, et al. Bone scintigram in cardiac amyloidosis: a case report. Clin Nucl Med 1981;6(3):105–8.PubMedCrossRef
47.
Ak I, Vardareli E, Erdinc O, et al. Myocardial Tc-99m MDP uptake on a bone scan in senile systemic amyloidosis with cardiac involvement. Clin Nucl Med 2000;25(10):826–7.PubMedCrossRef
48.
Fournier C, Grimon G, Rinaldi JP, et al. Usefulness of technetium-99m pyrophosphate myocardial scintigraphy in amyloid polyneuropathy and correlation with echocardiography. Am J Cardiol 1993;72(11):854–7.PubMedCrossRef
49.
Hongo M, Hirayama J, Fujii T, et al. Early identification of amyloid heart disease by technetium-99m-pyrophosphate scintigraphy: a study with familial amyloid polyneuropathy. Am Heart J 1987;113(3):654–62.PubMedCrossRef
50.
Davidson RM, Lin DS, Klima M. Temporal changes in myocardial uptake on serial bone scans in two cases of presumed senile cardiac amyloidosis. Clin Nucl Med 1993;18(10):858–62.PubMedCrossRef
51.
Goldstein SA, Lindsay J, Chandeysson PL, et al. Usefulness of technetium pyrophosphate scintigraphy in demonstrating cardiac amyloidosis in persons aged 85 years and older. Am J Cardiol 1989;63(11):752–3.PubMedCrossRef
52.
Wizenberg TA, Muz J, Sohn YH, et al. Value of positive myocardial technetium-99m-pyrophosphate scintigraphy in the non-invasive diagnosis of cardiac amyloidosis. Am Heart J 1982;103(4 Pt 1):468–73.PubMedCrossRef
53.
Falk RH, Lee VW, Rubinow A. Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis. Am J Cardiol 1983;51(5):826–30.PubMedCrossRef
54.
Lee VW, Caldarone AG, Falk RH, et al. Amyloidosis of heart and liver: comparison of Tc-99m pyrophosphate and Tc-99m methylene diphosphonate for detection. Radiology 1983;148(1):239–42.PubMed
55.
Eriksson P, Backman C, Bjerle P, et al. Non-invasive assessment of the presence and severity of cardiac amyloidosis. A study in familial amyloidosis with polyneuropathy by cross sectional echocardiography and technetium-99m pyrophosphate scintigraphy. Br Heart J 1984;52(3):321–6.PubMedCrossRef
56.
Janssen S, Piers DA, van Rijswijk MH, et al. Soft-tissue uptake of 99mTc-diphosphonate and 99mTc-pyrophosphate in amyloidosis. Eur J Nucl Med 1990;16(8-10):663–70.PubMedCrossRef
57.
Hartmann A, Frenkel J, Hopf R, et al. Is technetium-99m-pyrophosphate scintigraphy valuable in the diagnosis of cardiac amyloidosis? Int J Card Imaging 1990;5(4):227–31.PubMedCrossRef
58.
Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46(6):1076–84.PubMedCrossRef
59.
Bernstein LR. Mechanisms of therapeutic activity for gallium. Pharm Rev 1998;50(4):665–82.PubMed
60.
Braun SD, Lisbona R, Novales-Diaz JA, et al. Myocardial uptake of 99mTc-phosphate tracer in amyloidosis. Clin Nucl Med 1979;4(6):244–5.PubMedCrossRef
61.
Montes J, Lopez L, Chamorro JL, et al. Cardiac gallium uptake in amyloidosis. Eur J Nucl Med 1984;9(9):438.PubMedCrossRef
62.
Li CK, Rabinovitch MA, Juni JE, et al. Scintigraphic characterization of amyloid cardiomyopathy. Clin Nucl Med 1985;10(3):156–9.PubMedCrossRef
63.
Jain D, Crawly JC, Lahiri A, et al. Indium-111 antimyosin images compared with triphenyltetrazolium chloride staining in a patient six days after myocardial infarction. J Nucl Med 1990;31:231–3.PubMed
64.
Carrio I, Berna L, Ballester M, et al. Indium-111 antimyosin scintigraphy to assess myocardial damage in patients with suspected myocarditis and cardiac rejection. J Nucl Med 1988;29:1893–900.PubMed
65.
Lekakis J, Vassipoulos N, Psichoyiou H, et al. Doxorubicin cardiotoxicity detected by indium-111 myosin specific imaging. Eur J Nucl Med 1991;18:225–6.PubMedCrossRef
66.
Lekakis J, Nanas J, Moustafellou C, et al. Cardiac amyloidosis detected by indium-111 antimyosin imaging. Am Heart J 1992;124:1630–1.PubMedCrossRef
67.
Lekakis J, Dimopoulos M, Nanas J, et al. Antimyosin scintigraphy for detection of cardiac amyloidosis. Am J Cardiol 1997;80:963–5.PubMedCrossRef
68.
Aroney CN, Ruddy TD, Dighero H, et al. Differentiation of restrictive cardiomyopathy from pericardial constriction: assessment of diastolic function by radionuclide angiography. J Am Coll Cardiol 1989;13:1007–14.PubMedCrossRef
69.
Gerson MC, Colthar MS, Fowler NO. Differentiation of constrictive pericarditis and restrictive cardiomyopathy by radionuclide ventriculography. Am Heart J 1989;118:114–20.PubMedCrossRef
70.
Clements IP, Olson LJ, Scanlon PD, et al. The effect of respiration on left ventricular diastolic filling as assessed by radionuclide ventriculography. Nucl Med Commun 2000;21:55–63.PubMedCrossRef
71.
Hongo M, Fujii T, Hirayama J, et al. Radionuclide angiographic assessment of left ventricular diastolic filling in amyloid heart disease: a study of patients with familial amyloid polyneuropathy. J Am Coll Cardiol 1989;13:48–53.PubMed
72.
Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107:2440–5.PubMedCrossRef
73.
Dispenzieri A, Gertz MA, Kyle RA, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004;104(6):1881–7.PubMedCrossRef
74.
Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med 1990;323:508–13.PubMed
75.
Hazenberg BP, van Rijswijk MH, Piers DA, et al. Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med 2006;119:355.e15–e24.CrossRef
76.
Jager PL, Hazenberg BP, Franssen EJF, et al. Kinetic studies with iodine-123-labeled serum amyloid P component in patients with systemic AA and AL amyloidosis and assessment of clinical value. J Nucl Med 1998;39:699–706.PubMed
77.
Hazenberg BP, Van Rijswijk MH, Lub-de Hooge M, et al. Diagnostic performance and prognostic value of extravascular retention of 123I-labeled serum amyloid P component in systemic amyloidosis. J Nucl Med 2007;48(6):865–72.PubMedCrossRef
78.
Yadav S, Sharma S, Gilfillan I. Unusual positron emission tomography findings in pulmonary amyloidosis: a case report. J Cardiothorac Surg 2006;1:32.PubMedCrossRef
79.
Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 2004;55(3):306–19.PubMedCrossRef
80.
Rabinovici GD, Furst AJ, O’Neil JP, et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2007;68:1205–12.PubMedCrossRef
Metadata
Title
Nuclear imaging in cardiac amyloidosis
Authors
A. W. J. M. Glaudemans
R. H. J. A. Slart
C. J. Zeebregts
N. C. Veltman
R. A. Tio
B. P. C. Hazenberg
R. A. J. O. Dierckx
Publication date
01-04-2009
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 4/2009
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-008-1037-1

Other articles of this Issue 4/2009

European Journal of Nuclear Medicine and Molecular Imaging 4/2009 Go to the issue

Letter to the Editor

Determinants of 131I radiation dose to thyroid follicular cells

Original Article

Standardization of the heart-to-mediastinum ratio of 123I-labelled-metaiodobenzylguanidine uptake using the dual energy window method: feasibility of correction with different camera–collimator combinations

Focus on

SUV and segmentation: pressing challenges in tumour assessment and treatment

Society Communications

Society Communications April 09

Original Article

Quantification of (R)-[11C]PK11195 binding in rheumatoid arthritis

Image of the Month

Functional neuroimaging in Hashimoto’s encephalitis: a physiopathological imaging?